Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
Thomas J. Fuchs appointed as Lilly's first Chief AI Officer
Eli Lilly and Company appoints their first Chief AI Officer in Thomas J. Fuchs, to spearhead the strategic direction and leadership of AI.
Read more
New AI-focused RNA collaboration for Eli Lilly
Eli Lilly has entered into a research collaboration with Genetic Leap, a private company focused on AI, to advance the development of RNA-based genetic medicines.
NICE endorses Novartis’ take home drug for rare blood disorder
NICE recommends an oral therapy for adults with PNH, marking the 1000th medicine evaluated since its inception in 1999.
Sanofi's MS drug delivers surprising Phase III results
It’s been both a good and bad week for French pharmaceutical company Sanofi, as their MS drug candidate, received mixed trial results.
Second mpox vaccine wins FDA approval
The FDA has formally approved Emergent BioSolutions’ smallpox and mpox vaccine for use in preventing the virus in people at high risk of infection.
Novartis and Lindy Biosciences enter drug delivery partnership
The deal centres on Lindy’s microglassification technology, which facilitates high-concentration subcutaneous injections of biologic drugs.
UK government unveils £400m plan to boost life science sector
The UK Government has launched a £400m public-private investment initiative, aiming to advance the pharmaceutical and life sciences sectors.
Spotlight: August 2024
Catch up on the top pharma news stories from August in our monthly round-up. From the latest on the spread of mpox to new treatment approvals, there’s plenty to discover.
Spoonful of Technology: July-August 2024
We look at the latest examples of how pharma and its partners are working together to develop technology to solve key healthcare challenges.
Loading posts...
« Previous
1
2
3
4
5
…
15
Next »